Neurosense Therapeutics is trading 5.2% lower at $3.73 after-hours on October 2 after a reported Nasdaq delisting determination for missing the $35 million market-value requirement by September 29; it plans to appeal, though its investor-news page did not confirm the notice. - Shares fell from $7.40 on September 24 to a $3.94 regular-session close on October 2. - The broad market rose, making market weakness a poor fit; listing-compliance news is the clearest explanation if confirmed.